Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis

Description

List of Tables

This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Atopic Dermatitis market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033.

GlobalData estimated that the atopic dermatitis market was $8.5 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $22.5 billion, increasing at a compound annual growth rate (CAGR) of 10.2%. This strong growth will be fuelled by driven by the launch of 17 late-stage pipeline agents, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast period.

Scope

Overview of AD - including epidemiology, disease etiology and management.
Topline AD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the seven-market atopic dermatitis (AD) therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the seven-market AD therapeutics market from 2023-2033.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC314PIDR

1 Atopic Dermatitis: Executive Summary

1.1 AD market to experience significant growth from 2023-33
1.2 New players set to enter AD market
1.3 Opportunities remain for the treatment of AD
1.4 Novel systemic therapies dominate the late-stage pipeline
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumption and methods: 12-month diagnosed prevalent cases of AD
- 4.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of AD by severity 4.5 Epidemiological Forecast for AD (2023-33)
- 4.5.1 12-month diagnosed prevalent cases of AD
- 4.5.2 Age-specific 12-month diagnosed prevalent cases of AD
- 4.5.3 Sex-specific 12-month diagnosed prevalent cases of AD
- 4.5.4 12-month diagnosed prevalent cases of AD by severity
4.6 Discussion
- 4.6.1 COVID-19 impact
- 4.6.2 Limitations of the analysis
- 4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
- 5.2.1 Treatment approach

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 More personalized treatments through improved diagnosis
7.3 High cost of therapeutics
7.4 Lack of therapeutic options for CHE
7.5 Better long-term disease control and management

8 R&D Strategies

8.1 Overview
- 8.1.1 Rise of the JAK inhibitors
- 8.1.2 Rise of IL-inhibiting biologics
- 8.1.3 Personalized approach for AD
- 8.1.4 Promising effects of anti-OX40/OX40L therapies
8.2 Clinical trials design
- 8.2.1 Clinical trial design in AD
- 8.2.2 Clinical trial design in CHE
- 8.2.3 H2H in AD

9 Pipeline Assessment

9.1 Overview 9.2 Promising drugs in clinical development
- 9.2.1 Mild to moderate AD agents
- 9.2.2 Moderate-to-severe agents

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment
- 10.2.1 Systemic agents
- 10.2.2 Topical agents

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - KOLs and payers interviewed for this report
- 13.4.1 KOLs 13.5 Primary research - prescriber survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Managing Analyst
- 13.6.3 Therapy Area Director
- 13.6.4 Epidemiologist
- 13.6.5 Reviewers
- 13.6.6 Vice President of Disease Intelligence and Epidemiology
- 13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC314PIDR

List of Table

List of Tables

Table 1: AD: Key metrics in the 7MM
Table 2: Risk factors and comorbidities for AD
Table 3: Treatment guidelines for AD
Table 4: AD approvals across 7MM
Table 5: Top 10 deals by value, 2019-25
Table 6: AD market - global drivers and barriers, 2023-33
Table 7: Key events impacting sales for AD in the US, 2023-33
Table 8: AD market - drivers and barriers in the US, 2023-33
Table 9: Key events impacting sales for AD in the 5EU, 2023-33
Table 10: AD market - drivers and barriers in the 5EU, 2023-33
Table 11: Key events impacting sales for AD in Japan, 2023-33
Table 12: AD market - drivers and barriers in Japan, 2023-33
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for AD in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in AD during the forecast period
Figure 3: Competitive assessment of the marketed and pipeline systemic drugs benchmarked against the SOC, Dupixent
Figure 5: Major drug targets in AD treatment
Figure 6: 7MM, 12-month diagnosed prevalence of AD, %, all ages, 2023
Figure 7: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the adult population
Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population
Figure 9: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the adult population by severity
Figure 10: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population by severity
Figure 11 presents the 12-month diagnosed prevalent cases of AD in the 7MM in 2023.
Figure 11: 7MM, 12-month diagnosed prevalent cases of AD, N, both sexes, all ages, 2023
Figure 12: 7MM, 12-month diagnosed prevalent cases of AD by age, N, both sexes, 2023
Figure 13 presents the 12-month diagnosed prevalent cases of AD by sex in the 7MM in 2023.
Figure 13: 7MM, 12-month diagnosed prevalent cases of AD by sex, N, all ages, 2023
Figure 14 presents the 12-month diagnosed prevalent cases of AD by severity in the 7MM in 2023.
Figure 14: 7MM, 12-month diagnosed prevalent cases of AD by severity, both sexes, N, all ages, 2023
Figure 15: Flowchart of the diagnosis and management of AD, according to AAD
Figure 16: Unmet needs and opportunities in AD
Figure 17: Overview of the development pipeline in AD
Figure 18: Key late-stage trials for the promising mild-to-moderate pipeline agents that GlobalData expects to be licensed for AD in the 7MM during the forecast period
Figure 19: Key late-stage trials for promising moderate-to-severe pipeline agents that GlobalData expects to be licensed for AD in the 7MM during the forecast period
Figure 20: Competitive assessment of marketed and pipeline systemic drugs benchmarked against the SOC, Dupixent
Figure 21: Competitive assessment of the marketed and pipeline topical drugs, benchmarked against the SOC, TCs.
Figure 22: Analysis of the company portfolio gap in AD during the forecast period, 2023-33
Figure 23: Global (7MM) sales forecast by country for AD in 2023 and 2033
Figure 24: Global (7MM) Sales Forecast by MOA for AD in 2023 and 2033
Figure 25: Sales forecast by class for AD in the US in 2023 and 2033
Figure 26: Sales forecast by class for AD in the 5EU in 2023 and 2033
Figure 27: Sales forecast by class for AD in Japan in 2023 and 2033

Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Atopic Dermatitis: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures